Stock screenerAll disclosures →
EDGAR →
CLYM
Conviction 96HealthcareScan · Thu, Jun 25, 2026CLYM$12.65-0.78%
ResistanceSupportVol 14Vol MA14 1.45M
Mar 26Apr 14May 1May 19Jun 8Jun 25
Price12.65
Change-0.78%
Gap+0.78%
Rel volume1.80×
Avg volume1.41M
Avg $ vol16.15M
SMA 2011.36
SMA 5010.65
SMA 2005.71
Price vs 50+18.74%
Price vs 200+121.63%
MA stackbullish
50/200 cross—
Supertrendup · 10.23
RSI (14)63
MACD hist0.13
MACD crossbull · 3d
Stoch %K / %D75 / 87
ADX (14)29
+DI / −DI26 / 10
RSI divergence—
MACD divergence—
ATR %+7.30%
ADR %8.69%
52w high12.75
52w low1.18
From 52w high-0.78%
Above 52w low+972.03%
New 52w highNo
SqueezeFired
Bollinger width23.10%
%B0.99
Donchian pos76.21%
Donchian high13.43
Donchian low10.15
AVWAP (52w high)12.89
vs AVWAP high-1.89%
AVWAP (52w low)5.41
vs AVWAP low+134.01%
OBV trendUp
Chaikin MF (20)-0.11
Today vs 20d1.80×
Avg vol (14d)1.45M
Avg vol (20d)1.41M
Avg $ vol (20d)16.15M
Market cap724.35M
RS 3m (vs SPY)+78.61%
RS 6m (vs SPY)+190.16%
RS line new highYes
Trend template8/8
Technical rank93.4
1 week+11.55%
1 month+11.06%
3 months+81.23%
6 months+158.16%
1 year+880.62%
YTD+237.33%
P/E-12.10
P/B4.89
P/S—
P/FCF-13.28
EPS-0.8800
Div yield—
ROE-40.42%
ROA-39.28%
Debt/Eq—
Current27.86
EV/EBITDA-10.56
Gross margin—
Net margin—
Rev growth—
EPS growth19.01%
Price target21.56
Target upside70.43%
Analyst ratingBuy
Institutional59.73%
Ent. value715.99M
Revenue—
Net income-13.72M
Gross profit—
Free cash flow-54.54M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out57.26M
Employees29
ListedTue, Aug 10, 2021
Free float19.95M
Float %41.8%
Short interest1.91M
Days to cover2.8d
Short volume66.9%
Squeeze score63 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$0.20 vs −$0.26
Last surprise+23.1% beat
Setup gradeA+
Conviction96 / 100
Pattern quality—
Tech rank93.4 / 100
Group rank50 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance12.48
Support8.58
Days since event—
Candle confirm—
News sentiment—
Financials as of Tue, Mar 31, 2026 · quarterly.
Congress activity
Disclosed STOCK Act trades in CLYM
No recent disclosed trades by Congress in CLYM. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in CLYM · 10 buys
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Kolchinsky Peter Director · Stock Option (Right to Buy) · 2026-06-05 | Grant | 40K | $0 | 2026-06-05 | 2026-06-08 |
RA Capital Healthcare Fund LP Director · Stock Option (Right to Buy) · 2026-06-05 | Grant | 40K | $0 | 2026-06-05 | 2026-06-08 |
RA Capital Nexus Fund III, L.P. Director · Stock Option (Right to Buy) · 2026-06-05 | Grant | 40K | $0 | 2026-06-05 | 2026-06-08 |
Drapkin Kimberlee C Director · Stock Option (Right to Buy) · 2026-06-05 | Grant | 40K | $0 | 2026-06-05 | 2026-06-08 |
WILLIAMS DOUGLAS E Director · Stock Option (Right to Buy) · 2026-06-05 | Grant | 40K | $0 | 2026-06-05 | 2026-06-08 |
Thomas Stephen Basil Director · Stock Option (Right to Buy) · 2026-06-05 | Grant | 40K | $0 | 2026-06-05 | 2026-06-08 |
RA CAPITAL MANAGEMENT, L.P. Director · Stock Option (Right to Buy) · 2026-06-05 | Grant | 40K | $0 | 2026-06-05 | 2026-06-08 |
RA Capital Nexus Fund II, L.P. Director · Stock Option (Right to Buy) · 2026-06-05 | Grant | 40K | $0 | 2026-06-05 | 2026-06-08 |
Cumbo Alexander Director · Stock Option (Right to Buy) · 2026-06-05 | Grant | 40K | $0 | 2026-06-05 | 2026-06-08 |
RA Capital Nexus Fund, L.P. Director · Stock Option (Right to Buy) · 2026-06-05 | Grant | 40K | $0 | 2026-06-05 | 2026-06-08 |
SEC filings
EDGAR filings in CLYM · 6 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.
Start free — 7-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.